Literature DB >> 29909488

Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy.

Takahito Sugase1, Tomoki Makino2, Makoto Yamasaki1, Koji Tanaka1, Tadayoshi Hashimoto1, Yasuhiro Miyazaki1, Tsuyoshi Takahashi1, Yukinori Kurokawa1, Kiyokazu Nakajima1, Masayuki Mano3, Eiichi Morii4, Masaki Mori1, Yuichiro Doki1.   

Abstract

INTRODUCTION: We aimed to analyze the clinical and histological effects of chemotherapy in superficial esophageal squamous cell carcinoma (SESCC).
METHODS: We analyzed tumor samples from five patients with cT1bN1M0 who underwent subtotal esophagectomy following two courses of a new triplet chemotherapy regimen including docetaxel, cisplatin, and 5-fluorouracil (DCF). To assess the histological effects of chemotherapy, resected specimens were analyzed by macroscopic examination, hematoxylin & eosin (HE) staining, immunohistochemical (IHC) staining (p53, Ki-67 and cytokeratin) and periodic acid-Schiff (PAS) staining.
RESULTS: All five patients had a pathological T stage of T0/1a-LPM/1a-MM/1b (1/2/1/1) and histological grade of grade1a/1b/2/3 (1/1/2/1). Endoscopic examination revealed substantial shrinkage of lugol-voiding lesions (LVLs) in all cases. One case showed complete LVL disappearance, and resected specimen examination confirmed pathological complete response (pCR). IHC and PAS staining revealed that most initial LVLs were PAS-negative. Obvious viable cells were confirmed in two cases. The other three cases exhibited nuclear atypia and strong expression of p53 and Ki-67 in the basal layer of mucosa or lamina propria mucosae, even though the superficial layer of mucosa showed no obvious LVLs with PAS-positive. p53-positive lesions were also observed in Ki-67-positive. This indicated discordance between the endoscopic findings and histopathological evaluation.
CONCLUSION: DCF chemotherapy alone had a substantial therapeutic effect on SESCC in all cases. However, despite the normal appearance of the mucosal surface, viable cancer cells remained below the basal layer of mucosa. Careful attention should be paid when diagnosing clinical CR, or securing a resection margin of SESCC after DCF chemotherapy.

Entities:  

Keywords:  Chemotherapy; Cytokeratin; Histopathology; Ki-67; Superficial esophageal cancer; p53

Year:  2018        PMID: 29909488     DOI: 10.1007/s10388-018-0626-8

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  31 in total

1.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

2.  Treatment evaluation of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma.

Authors:  Goshi Nishimura; Hideki Matsuda; Takahide Taguchi; Masahiro Takahashi; Masanori Komatsu; Daisuke Sano; Naoko Sakuma; Yasuhiro Arai; Hideaki Takahashi
Journal:  Anticancer Res       Date:  2012-02       Impact factor: 2.480

Review 3.  Endoscopic management of esophageal cancer after definitive chemoradiotherapy.

Authors:  Sajneet K Khangura; Bruce D Greenwald
Journal:  Dig Dis Sci       Date:  2013-01-17       Impact factor: 3.199

4.  Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma.

Authors:  Sachiko Yamamoto; Ryu Ishihara; Masaaki Motoori; Yoshifumi Kawaguchi; Noriya Uedo; Yoji Takeuchi; Koji Higashino; Masahiko Yano; Satoaki Nakamura; Hiroyasu Iishi
Journal:  Am J Gastroenterol       Date:  2011-02-22       Impact factor: 10.864

5.  Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.

Authors:  Genta Sawada; Atsushi Niida; Ryutaro Uchi; Hidenari Hirata; Teppei Shimamura; Yutaka Suzuki; Yuichi Shiraishi; Kenichi Chiba; Seiya Imoto; Yusuke Takahashi; Takeshi Iwaya; Tomoya Sudo; Tomoatsu Hayashi; Hiroki Takai; Yoshihiro Kawasaki; Takashi Matsukawa; Hidetoshi Eguchi; Keishi Sugimachi; Fumiaki Tanaka; Hiromichi Suzuki; Ken Yamamoto; Hideshi Ishii; Makiko Shimizu; Hiroshi Yamazaki; Makoto Yamazaki; Yuji Tachimori; Yoshiaki Kajiyama; Shoji Natsugoe; Hiromasa Fujita; Kenichi Mafune; Yoichi Tanaka; David P Kelsell; Claire A Scott; Shoji Tsuji; Shinichi Yachida; Tatsuhiro Shibata; Sumio Sugano; Yuichiro Doki; Tetsu Akiyama; Hiroyuki Aburatani; Seishi Ogawa; Satoru Miyano; Masaki Mori; Koshi Mimori
Journal:  Gastroenterology       Date:  2016-02-10       Impact factor: 22.682

Review 6.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

7.  Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Authors:  T Yano; M Muto; S Hattori; K Minashi; M Onozawa; K Nihei; S Ishikura; A Ohtsu; S Yoshida
Journal:  Endoscopy       Date:  2008-09-04       Impact factor: 10.093

8.  TP53 gene mutation profile in esophageal squamous cell carcinomas.

Authors:  M P Audrézet; M Robaszkiewicz; B Mercier; J B Nousbaum; J P Bail; E Hardy; A Volant; P Lozac'h; J F Charles; H Gouéron
Journal:  Cancer Res       Date:  1993-12-01       Impact factor: 12.701

9.  Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).

Authors:  Shuichi Hironaka; Yasuhiro Tsubosa; Junki Mizusawa; Takayuki Kii; Ken Kato; Takahiro Tsushima; Keisho Chin; Akihisa Tomori; Tatsuya Okuno; Toshikatsu Taniki; Takashi Ura; Hisayuki Matsushita; Takashi Kojima; Yuichiro Doki; Hitoshi Kusaba; Kazumasa Fujitani; Koichi Taira; Shiko Seki; Tsutomu Nakamura; Yuko Kitagawa
Journal:  Cancer Sci       Date:  2014-09       Impact factor: 6.716

10.  Japanese Classification of Esophageal Cancer, 11th Edition: part I.

Authors: 
Journal:  Esophagus       Date:  2016-11-10       Impact factor: 4.230

View more
  1 in total

1.  Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial.

Authors:  Osamu Shiraishi; Tomoki Makino; Makoto Yamasaki; Koji Tanaka; Kotaro Yamashita; Tomo Ishida; Keijiro Sugimura; Hiroshi Miyata; Masaaki Motoori; Kazumasa Fujitani; Atsushi Takeno; Motohiro Hirao; Yutaka Kimura; Taroh Satoh; Masahiko Yano; Yuichiro Doki; Takushi Yasuda
Journal:  Esophagus       Date:  2021-03-18       Impact factor: 4.230

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.